Histone deacetylase 3 is required for maintenance of bone mass during aging

Bone

Volumn 52, Issue 1, 2013, Pages 296-307

  McGee Lawrence, Meghan E ^a   Bradley, Elizabeth W ^a   Dudakovic, Amel ^a   Carlson, Samuel W ^a   Ryan, Zachary C ^a   Kumar, Rajiv ^a   Dadsetan, Mahrokh ^a   Yaszemski, Michael J ^a,b   Chen, Qingshan ^b   An, Kai Nan ^a,b   Westendorf, Jennifer J ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

DNA damage; Histone deacetylase; Osteoblast; Osteocalcin Cre; Osteocyte

Indexed keywords

CRE RECOMBINASE; DNA; HISTONE; HISTONE DEACETYLASE 3; LYSINE; OSTEOCALCIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR ZFP521; UNCLASSIFIED DRUG;

AGING; ANIMAL EXPERIMENT; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERALIZATION; CONTROLLED STUDY; DNA DAMAGE; EPIGENETICS; FEMALE; FRACTURE; GENE CONTROL; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSSIFICATION; OSTEOBLAST; OSTEOCYTE; OSTEOLYSIS; PROTEIN EXPRESSION; SKELETON;

ABSORPTIOMETRY, PHOTON; AGING; ANIMALS; BASE SEQUENCE; BONE DENSITY; DNA DAMAGE; DNA PRIMERS; HISTONE DEACETYLASES; IMMUNOHISTOCHEMISTRY; MICE; MICE, KNOCKOUT; OSTEOCALCIN; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC;

EID: 84868503739     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.10.015     Document Type: Article

References (51)

1. Glozak M.A., Sengupta N., Zhang X., Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005, 363:15-23.
2. Jeon E.J., Lee K.Y., Choi N.S., Lee M.H., Kim H.N., Jin Y.H., et al. Bone morphogenetic protein-2 stimulates Runx2 acetylation. J Biol Chem 2006, 281:16502-16511.
3. Schroeder T.M., Kahler R.A., Li X., Westendorf J.J. Histone deacetylase 3 interacts with runx2 to repress the osteocalcin promoter and regulate osteoblast differentiation. J Biol Chem 2004, 279:41998-42007.
4. Hesse E., Saito H., Kiviranta R., Correa D., Yamana K., Neff L., et al. Zfp521 controls bone mass by HDAC3-dependent attenuation of Runx2 activity. J Cell Biol 2010, 191:1271-1283.
5. Juan L.J., Shia W.J., Chen M.H., Yang W.M., Seto E., Lin Y.S., et al. Histone deacetylases specifically down-regulate p53-dependent gene activation. J Biol Chem 2000, 275:20436-20443.
6. Luo J., Su F., Chen D., Shiloh A., Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 2000, 408:377-381.
7. Zhang F., Shi Y., Wang L., Sriram S. Role of HDAC3 on p53 expression and apoptosis in T cells of patients with multiple sclerosis. PLoS One 2011, 6:e16795.
8. Haberland M., Mokalled M.H., Montgomery R.L., Olson E.N. Epigenetic control of skull morphogenesis by histone deacetylase 8. Genes Dev 2009, 23:1625-1630.
9. Vega R.B., Matsuda K., Oh J., Barbosa A.C., Yang X., Meadows E., et al. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 2004, 119:555-566.
10. Zhang Y., Kwon S., Yamaguchi T., Cubizolles F., Rousseaux S., Kneissel M., et al. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol 2008, 28:1688-1701.
11. McGee-Lawrence M.E., McCleary-Wheeler A.L., Secreto F.J., Razidlo D.F., Zhang M., Stensgard B.A., et al. Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts. Bone 2011, 48:1117-1126.
12. Pratap J., Akech J., Wixted J.J., Szabo G., Hussain S., McGee-Lawrence M.E., et al. The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. Mol Cancer Ther 2010, 9:3210-3220.
13. Senn S.M., Kantor S., Poulton I.J., Morris M.J., Sims N.A., O'Brien T.J., et al. Adverse effects of valproate on bone: defining a model to investigate the pathophysiology. Epilepsia 2010, 51:984-993.
14. Westendorf J.J. Histone deacetylases in control of skeletogenesis. J Cell Biochem 2007, 102:332-340.
15. Westendorf J.J., Zaidi S.K., Cascino J.E., Kahler R., van Wijnen A.J., Lian J.B., et al. Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Cell Biol 2002, 22:7982-7992.
16. Bhaskara S., Chyla B.J., Amann J.M., Knutson S.K., Cortez D., Sun Z.W., et al. Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol Cell 2008, 30:61-72.
17. Razidlo D.F., Whitney T.J., Casper M.E., McGee-Lawrence M.E., Stensgard B.A., Li X., et al. Histone deacetylase 3 depletion in osteo/chondroprogenitor cells decreases bone density and increases marrow fat. PLoS One 2010, 5:e11492.
18. Bradley E.W., Razidlo D.R., Stensgard B., Westendorf J.J. Hdac3 Controls Growth Plate Matrix Secretion and Akt/mTOR Pathway Activation. ASBMR 2011 Annual Meeting 2011, FR0086. American Society for Bone and Mineral Research, San Diego, CA.
19. Zhang M., Xuan S., Bouxsein M.L., von Stechow D., Akeno N., Faugere M.C., et al. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem 2002, 277:44005-44012.
20. Knutson S.K., Chyla B.J., Amann J.M., Bhaskara S., Huppert S.S., Hiebert S.W. Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks. EMBO J 2008, 27:1017-1028.
21. Clemens T.L., Tang H., Maeda S., Kesterson R.A., Demayo F., Pike J.W., et al. Analysis of osteocalcin expression in transgenic mice reveals a species difference in vitamin D regulation of mouse and human osteocalcin genes. J Bone Miner Res 1997, 12:1570-1576.
22. VanKoevering K.K., Williams B.O. Transgenic mouse strains for conditional gene deletion during skeletal development. IBMS BoneKEy 2008, 5:151-170.
23. Komori T., Yagi H., Nomura S., Yamaguchi A., Sasaki K., Deguchi K., et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997, 89:755-764.
24. Bouxsein M.L., Boyd S.K., Christiansen B.A., Guldberg R.E., Jepsen K.J., Muller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 2010, 25:1468-1486.
25. Norman J., Shapter J.G., Short K., Smith L.J., Fazzalari N.L. Micromechanical properties of human trabecular bone: a hierarchical investigation using nanoindentation. J Biomed Mater Res A 2008, 87:196-202.
26. Mittra E., Akella S., Qin Y.X. The effects of embedding material, loading rate and magnitude, and penetration depth in nanoindentation of trabecular bone. J Biomed Mater Res A 2006, 79:86-93.
27. Chen Q., Rho J.Y., Fan Z., Laulederkind S.J., Raghow R. Congenital lack of COX-2 affects mechanical and geometric properties of bone in mice. Calcif Tissue Int 2003, 73:387-392.
28. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987, 2:595-610.
29. Gosset M., Berenbaum F., Thirion S., Jacques C. Primary culture and phenotyping of murine chondrocytes. Nat Protoc 2008, 3:1253-1260.
30. Soung do Y., Dong Y., Wang Y., Zuscik M.J., Schwarz E.M., O'Keefe R.J., et al. Runx3/AML2/Cbfa3 regulates early and late chondrocyte differentiation. J Bone Miner Res 2007, 22:1260-1270.
31. Bradley E.W., Drissi M.H. Wnt5b regulates mesenchymal cell aggregation and chondrocyte differentiation through the planar cell polarity pathway. J Cell Physiol 2011, 226:1683-1693.
32. Bradley E.W., Drissi M.H. WNT5A regulates chondrocyte differentiation through differential use of the CaN/NFAT and IKK/NF-kappaB pathways. Mol Endocrinol 2010, 24:1581-1593.
33. Feng D., Liu T., Sun Z., Bugge A., Mullican S.E., Alenghat T., et al. A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic lipid metabolism. Science 2011, 331:1315-1319.
34. Sun Z., Singh N., Mullican S.E., Everett L.J., Li L., Yuan L., et al. Diet-induced lethality due to deletion of the Hdac3 gene in heart and skeletal muscle. J Biol Chem 2011, 286:33301-33309.
35. Montgomery R.L., Potthoff M.J., Haberland M., Qi X., Matsuzaki S., Humphries K.M., et al. Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J Clin Invest 2008, 118:3588-3597.
36. Zhou X., Zhang Z., Feng J.Q., Dusevich V.M., Sinha K., Zhang H., et al. Multiple functions of Osterix are required for bone growth and homeostasis in postnatal mice. Proc Natl Acad Sci U S A 2010, 107:12919-12924.
37. Nakashima K., Zhou X., Kunkel G., Zhang Z., Deng J.M., Behringer R.R., et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002, 108:17-29.
38. Oh J.H., Park S.Y., de Crombrugghe B., Kim J.E. Chondrocyte-specific ablation of Osterix leads to impaired endochondral ossification. Biochem Biophys Res Commun 2012, 418:634-640.
39. Xiong J., Onal M., Jilka R.L., Weinstein R.S., Manolagas S.C., O'Brien C.A. Matrix-embedded cells control osteoclast formation. Nat Med 2011, 17:1235-1241.
40. Donnelly E., Chen D.X., Boskey A.L., Baker S.P., van der Meulen M.C. Contribution of mineral to bone structural behavior and tissue mechanical properties. Calcif Tissue Int 2010, 87:450-460.
41. Faibish D., Ott S.M., Boskey A.L. Mineral changes in osteoporosis: a review. Clin Orthop Relat Res 2006, 443:28-38.
42. Pienkowski D., Doers T.M., Monier-Faugere M.C., Geng Z., Camacho N.P., Boskey A.L., et al. Calcitonin alters bone quality in beagle dogs. J Bone Miner Res 1997, 12:1936-1943.
43. Rissanen J.P., Suominen M.I., Peng Z., Halleen J.M. Secreted tartrate-resistant acid phosphatase 5b is a Marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model. Calcif Tissue Int 2008, 82:108-115.
44. Aguirre J.I., Plotkin L.I., Stewart S.A., Weinstein R.S., Parfitt A.M., Manolagas S.C., et al. Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast recruitment and bone loss. J Bone Miner Res 2006, 21:605-615.
45. Hedgecock N.L., Hadi T., Chen A.A., Curtiss S.B., Martin R.B., Hazelwood S.J. Quantitative regional associations between remodeling, modeling, and osteocyte apoptosis and density in rabbit tibial midshafts. Bone 2007, 40:627-637.
46. Verborgt O., Tatton N.A., Majeska R.J., Schaffler M.B. Spatial distribution of Bax and Bcl-2 in osteocytes after bone fatigue: complementary roles in bone remodeling regulation?. J Bone Miner Res 2002, 17:907-914.
47. Cheung W.Y., Simmons C.A., You L. Osteocyte apoptosis regulates osteoclast precursor adhesion via osteocytic IL-6 secretion and endothelial ICAM-1 expression. Bone 2012, 50:104-110.
48. Bellido T., Ali A.A., Plotkin L.I., Fu Q., Gubrij I., Roberson P.K., et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 2003, 278:50259-50272.
49. Jilka R.L., Weinstein R.S., Bellido T., Roberson P., Parfitt A.M., Manolagas S.C. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999, 104:439-446.
50. Weinstein R.S. Glucocorticoid-induced osteonecrosis. Endocrinol Metab Clin North Am Sep 2012, 41(3):595-611.
51. Weinstein R.S., Nicholas R.W., Manolagas S.C. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab 2000, 85:2907-2912.